Lipitor

Lipitor. It is a statin medication used to lower low-density lipoprotein (LDL) cholesterol and prevent cardiovascular disease. Marketed by Pfizer, it became one of the best-selling pharmaceutical products in history. Its active pharmaceutical ingredient is atorvastatin calcium.

Medical uses

Lipitor is primarily prescribed for the treatment of dyslipidemia and the prevention of atherosclerotic cardiovascular disease. It is indicated to reduce elevated levels of total cholesterol, LDL cholesterol, and apolipoprotein B, and to increase high-density lipoprotein (HDL) cholesterol in patients with primary hypercholesterolemia. Clinical trials, such as the ASCOT-LLA and the CARDS trial, demonstrated its efficacy in reducing the risk of myocardial infarction and stroke in high-risk populations. It is also used in the management of patients with heterozygous familial hypercholesterolemia and to lower cholesterol in individuals with type 2 diabetes.

Adverse effects

Common adverse effects include musculoskeletal symptoms like myalgia and arthralgia, as well as gastrointestinal disturbances such as diarrhea and dyspepsia. A serious but rare risk is rhabdomyolysis, a severe muscle injury that can lead to acute kidney injury. Other potential effects involve elevated liver enzymes, indicating hepatotoxicity, and an increased incidence of new-onset diabetes observed in some long-term studies. The FDA mandates a warning regarding the risk of cognitive impairment, though evidence for this remains controversial.

Pharmacology

Lipitor works by competitively inhibiting the enzyme HMG-CoA reductase, which catalyzes the rate-limiting step in the mevalonate pathway of cholesterol biosynthesis in the liver. This inhibition depletes intracellular cholesterol stores, causing hepatocytes to upregulate LDL receptor expression on their surfaces. The increased receptor activity enhances clearance of LDL particles from the bloodstream, thereby lowering circulating cholesterol levels. It is metabolized primarily by the cytochrome P450 system, specifically via the CYP3A4 isoenzyme, leading to potential interactions with drugs like clarithromycin and itraconazole.

History

Atorvastatin was discovered by Bruce Roth and his team at Parke-Davis, a division of Warner-Lambert. The compound was patented in 1986 and received approval from the FDA in 1996. Following the merger of Warner-Lambert with Pfizer in 2000, the marketing and distribution of Lipitor were aggressively expanded under Pfizer's leadership. Its blockbuster status was cemented by the landmark Heart Protection Study and other major trials, leading to unprecedented global sales. The patent exclusivity in the United States expired in 2011, allowing for the introduction of numerous generic versions.

Society and culture

Lipitor's commercial success made it a cultural icon within the pharmaceutical industry, symbolizing the era of blockbuster drugs. Its marketing campaigns, including direct-to-consumer advertising, were highly influential and subject to analysis by entities like the Congressional Budget Office. The drug's patent expiration and the subsequent "patent cliff" had significant economic repercussions for Pfizer and the broader healthcare market. Its story is frequently cited in discussions about drug development, intellectual property law, and the economics of the Medicare Part D program.

Category:Drugs